Johnson & Johnson posts 23% rise in third-quarter profit

FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid - Copyright Brendan McDermid(Reuters)

By Reuters

Published on 15/10/2019 - 13:34•Updated 16/04/2024 - 10:06

Comments

(Reuters) - Johnson & Johnson <JNJ.N> on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Net earnings rose to $4.83 billion, or $1.81 per share, in the quarter, from $3.93 billion, or $1.44 per share, a year earlier.

(Reporting by Saumya Sibi Joseph and Ankur Banerjee in Bengaluru; Editing by Bernard Orr)

Comments

You might also like